Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22790692 | 0.89 | HRH3 (0.39) | SLC6A4SLC6A3HRH3EPHX1HSD11B1 | |
| SCHEMBL23696790 | 0.85 | — | — | |
| SCHEMBL14454184 | 0.82 | DRD2 (0.35) | CHRM3HRH3EPHX1SMN1; SMN2 | |
| SCHEMBL18233622 | 0.80 | NCF1 (0.38) | — | |
| SCHEMBL17039285 | 0.80 | CARM1 (0.43) | CHRM3HRH3CARM1PRMT6EPHX1 | |
| SCHEMBL24764898 | 0.79 | GNAO1 (0.40) | SLC6A4SLC6A3CARM1PRMT6EPHX1 | |
| SCHEMBL23693419 | 0.79 | DRD2 (0.41) | CARM1PRMT6 | |
| SCHEMBL24428797 | 0.78 | HRH3 (0.34) | CHRM3HRH3EPHX1HSD11B1SMN1; SMN2 | |
| SCHEMBL25123272 | 0.78 | SIGMAR1 (0.40) | HRH3EPHX1HSD11B1SMN1; SMN2 | |
| SCHEMBL22848538 | 0.77 | CHRM4 (0.38) | SLC6A4SLC6A3HRH3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | SLC6A4 2592/4885SLC6A3 1813/4885CHRM3 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.